SightfileU.S. market data from official filings

NUVECTIS PHARMA INC (NVCT)

Name: NUVECTIS PHARMA INC (NVCT) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001875558 · EDGAR filings · Updated 2026-07-01

NUVECTIS PHARMA INC (NVCT) has reported institutional ownership of 16.9%, with 62 institutional managers holding positions valued at $34.9M per the latest 13F reporting period.

Institutional ownership

16.9%

Institutional managers

Reported 13F value

$34.9M

Insider activity

32 trans.

$2.09M net buying

Latest updates

2026-07-01 — Insider transaction reported (Form 4)
2026-07-01 — Insider transaction reported (Form 4)
2026-06-30 — Current report (8-K) filed
2026-06-30 — Prospectus supplement (424B5) filed
2026-06-29 — Prospectus supplement (424B5) filed
2026-06-29 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NUVECTIS PHARMA INC has 62 institutional holders and institutional ownership of 16.9%.

Insider activity

Insiders reported 32 transactions (24 buys, 0 sells) across 9 reporting insiders, with a net reported value of $2.09M.

Related companies

PROTALIX BIOTHERAPEUTICS INC (PLX) · SEER INC (SEER) · HUMACYTE INC (HUMA) · FRACTYL HEALTH INC (GUTS) · CHAMPIONS ONCOLOGY (CSBR) · TSCAN THERAPEUTICS INC (TCRX)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-01.